ERBB2 and breast cancer: Of the four subtypes, approximately 20% of the total breast cancer cases are HER2-positive, where the tumors overexpress the human epidermal growth factor receptor type 2 (HER2) [4,5] and confer an aggressive tumor phenotype with a poor prognosis [6].